In the October issue of Thrombosis and Haemostasis, Geng et al reported treatment satisfaction with dabigatran versus warfarin among patients with atrial fibrillation (AF) in China.
1 This time-intensive, patient-centred study with high completion rate of standardized telephone interviews provides high-quality data and key insights from the patients' perspectives. At 6 months, 33.5% of patients had discontinued dabigatran compared with 19.2% for warfarin. The authors report no difference in the global Anti-Clot Treatment Scale (ACTS) Burdens score or the global ACTS Benefits score. The favourable effects of dabigatran regarding decreased concern for dietary or drug interactions and medication-related hassles were offset by the economic burden of dabigatran which is not covered by medical insurance in China. As noted by the authors, the cost of dabigatran is 70 times the cost of warfarin. Factors associated with treatment persistence included older age, longer duration of anticoagulation therapy, global ACTS Benefits score and warfarin therapy.
Other important findings of this study include the overall low proportion of patients in the registry receiving anticoagulant therapy, 27%, for stroke prevention. In addition, of the 4,511 patients in the registry receiving an oral anticoagulant, only 18.5% (n ¼ 834) were ultimately enrolled in the study. Prior to propensity score matching, warfarin-treated patients were older, had higher CHA 2 DS 2 -VASc scores, lower education level and longer duration of anticoagulation use. The investigators did not assess changes in patient satisfaction over time. One would anticipate different attitudes among patients newly starting an anticoagulant opposed to longer term users whose mere persistence is a marker of drug tolerability and patient acceptance. The reasons for medication discontinuation are also of note with 47.6% (dabigatran-treated patients) and 42.9% (warfarin-treated patients) stopping treatment for non-bleeding adverse events, and 13.1 and 11.4%, respectively, for minor bleeding.
Although initiation of anticoagulation among patients with AF remains a major global challenge, treatment persistence is an increasingly recognized major clinical hurdle. Reported rates of treatment persistence vary widely, including within country, depending on the population studied and methodology used to ascertain treatment exposure. Definitions of gaps in treatment that constitute permanent discontinuation vary across studies. In addition, observational studies restricted to new users of anticoagulant treatment provide different insights and conclusions than those studies composed of switchers, restarts or patients already established on treatment. In a retrospective study conducted in Ontario, Canada, investigators used administrative data to assess treatment discontinuation defined as a gap in dabigatran or rivaroxaban prescriptions of 14 days or greater. 7 Given the high morbidity and mortality associated with AF-related stroke, physician and patient thresholds to discontinue treatment and physician and patient reluctance to resume an anticoagulant warrant further study. 10 Geng et al found that nearly half of all discontinuations were for non-bleeding reasons. Access and out-of-pocket patient costs are major determinants of drug adherence and persistence. 11, 12 However, having paroxysmal versus permanent AF has also been associated with treatment discontinuation. 13 Certainly the mixed messages that patients receive regarding drug safety from the media warrant clarification by the medical community.
As recently demonstrated by the GARFIELD registry, progress has been made in extending appropriate treatment to patients with AF at high risk of stroke.
14 Targeted educational interventions as employed in the IMPACT AF trial are proven strategies to improve global use of anticoagulants for stroke prevention in AF. 15 Parallel with these efforts is increasing focus on the challenge of long-term medication persistence. 16, 17 Perhaps stated best by Raparelli et al, 'A multi-level approach, including patients' preferences, factors determining physicians'prescribing habits and healthcare system infrastructure and support, is warranted to improve initiation and adherence of anticoagulants'.
